Bio Green Med Solution AI Stock Analysis
Want to see BGMS full AI Analyst Report?
Bio Green Med Solution (BGMS) AI Stock Analysis
Bio Green Med Solution
(NASDAQ:BGMS)
The overall score of 42 reflects a high-risk, early-stage company with a weak financial foundation. The primary concern is the combination of deep unprofitability and ongoing cash burn, which is rapidly depleting the company's only strength: its debt-free balance sheet. This is compounded by a bearish technical trend and a complete lack of traditional valuation support. The nascent revenue growth is the sole positive signal, but it is not yet sufficient to offset the significant risks to the company's financial viability.
Bio Green Med Solution (BGMS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.70M
- Dividend Yield
- ―
- Average Volume (3M)
- 73.19K
- Price to Earnings (P/E)
- -0.2
- Beta (1Y)
- 1.02
- Revenue Growth
- 18510.00%
- EPS Growth
- 98.80%
- Country
- US
- Employees
- 12
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Pharmaceuticals
Bio Green Med Solution Business Overview & Revenue Model
Company Description
Bio Green Med Solution, Inc. (BGMS) operates as a multifaceted company, with active involvement in both the fire protection and biopharmaceutical industries. The organization recently broadened its capabilities by completing the acquisition of Fitter...
Bio Green Med Solution Earnings Call Summary
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.
Bio Green Med Solution Financial Statement Overview
Summary
Financial performance is highly speculative. The dramatic revenue ramp to $1.86M TTM is a key strength, but profitability remains deeply negative with a -118% net loss margin. The pristine, debt-free balance sheet (score 72) provides a temporary runway, yet it is being rapidly eroded by persistent losses. Cash flow is the weakest link (score 28), with ongoing cash burn of -$1.1M TTM, making the company reliant on existing reserves.
Income Statement
35NegativeBalance Sheet
72PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86M | 747.00K | 43.00K | 420.00K | 0 | 0 |
| Gross Profit | 360.00K | 138.00K | 43.00K | 420.00K | -32.00K | -43.00K |
| EBITDA | -2.73M | -8.42M | -12.00M | -25.42M | -27.62M | -22.35M |
| Net Income | -2.20M | -3.00M | -11.21M | -22.55M | -21.20M | -18.46M |
Balance Sheet | ||||||
| Total Assets | 7.85M | 8.19M | 4.09M | 8.80M | 28.05M | 43.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.79M | 3.50M | 3.14M | 3.38M | 18.34M | 36.56M |
| Total Debt | 0 | 2,000 | 0 | 37.00K | 106.00K | 30.00K |
| Total Liabilities | 694.00K | 1.34M | 6.27M | 8.20M | 7.62M | 5.44M |
| Stockholders Equity | 7.16M | 6.84M | -2.17M | 607.00K | 20.43M | 37.69M |
Cash Flow | ||||||
| Free Cash Flow | -1.10M | -4.77M | -7.99M | -16.12M | -20.83M | -18.57M |
| Operating Cash Flow | -1.10M | -4.77M | -7.99M | -16.11M | -20.83M | -18.54M |
| Investing Cash Flow | -1,000 | 0 | 0 | -6,000 | -7,000 | -27.00K |
| Financing Cash Flow | 616.00K | 5.26M | 7.82M | 848.00K | 3.00M | 21.74M |
Bio Green Med Solution Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.89, below the 50-day MA of 0.90, and below the 200-day MA of 0.94, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 30.70 is Neutral, neither overbought nor oversold. The STOCH value of 21.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BGMS.
Bio Green Med Solution Risk Analysis
Bio Green Med Solution disclosed 63 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksBio Green Med Solution Peers Comparison
Overall Rating
NEUP48Neutral
BJDX44Neutral
RNTX43Neutral- BGMS42Neutral
BDRX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| NEUP | 48Neutral | $14.66M | -0.35 | -77.03% | ― | ― | ― |
| BJDX | 44Neutral | $3.13M | -0.07 | -125.01% | ― | ― | 93.91% |
| RNTX | 43Neutral | $52.28M | -0.30 | -234.45% | ― | ― | 36.23% |
| BGMS | 42Neutral | $4.44M | -0.20 | -31.60% | ― | 18510.00% | 98.80% |
| BDRX | 40Underperform | $1.26M | -45.33 | -42.42% | ― | ― | 97.97% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BGMS | Bio Green Med Solution, Inc. | 0.71 | -0.60 | -45.80% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.38 | -216.82 | -98.91% | |
| RNTX | Rein Therapeutics, Inc | 0.56 | -0.69 | -55.20% | |
| BJDX | Bluejay Diagnostics, Inc. | 2.60 | -21.07 | -89.00% | |
| NEUP | Neuphoria Therapeutics Inc. | 2.58 | -2.21 | -46.14% |
Bio Green Med Solution Corporate Events
Bio Green Med Solution Declares Quarterly Preferred Dividend
PositiveOn October 15, 2026, Bio Green Med Solution, Inc.’s board declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend was scheduled to be paid on November 1, 2026, to preferred shareholders o...
Bio Green Med Solution Reports Improved Q2 2026 Results
PositiveBio Green Med Solution Inc., a Malaysia-headquartered Nasdaq-listed company, has transitioned from its former biopharmaceutical focus to a core business in fire safety protection and equipment distribution since acquiring Fitters Sdn. Bhd. in Septemb...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 17, 2026